ESCAPE is partnering with patients and caregivers to develop novel, oral, precision therapeutics. We have established a research program to support development of a targeted precision medicine for patients who have a specific genetic mutation in their LRRK2 gene (pronounced “lark-two”). Visit our dedicated website to see if you qualify for genetic testing and find detailed information on the research program at clinicaltrials.gov.